Vectors Research Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Vectors Research Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,000	Closed	-$5K	–	544
2019 Q3	$5K	Hold	1,000	–	–	﹤0.01%	340
2019 Q2	$4K	Hold	1,000	–	–	﹤0.01%	331
2019 Q1	$5K	Hold	1,000	–	–	﹤0.01%	320
2018 Q4	$2K	Hold	1,000	–	–	﹤0.01%	592
2018 Q3	$3K	Buy	+1,000	New	+$3.13K	﹤0.01%	419

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Vectors Research Management's CPRX Position: Q4 2019 in Review

Vectors Research Management sold out of Catalyst Pharmaceutical (CPRX) in Q4 2019, closing a stake of 1,000 shares — an estimated $5K sold.

Vectors Research Management first reported a position in CPRX in Q3 2018 and held it in 5 quarters. The position peaked at $5K in Q3 2019. 130 funds tracked by Wall St. Rank hold CPRX as of Q4 2019.

Vectors Research Management reported no remaining Catalyst Pharmaceutical position as of Q4 2019 after selling out during the quarter.
Vectors Research Management sold 1,000 Catalyst Pharmaceutical shares in Q4 2019, an estimated $5K.
Vectors Research Management first reported a position in Catalyst Pharmaceutical in Q3 2018 and held it in 5 quarters.
Vectors Research Management's Catalyst Pharmaceutical position peaked at $5K in Q3 2019.
130 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2019.

Based on Vectors Research Management's 13F filing for Q4 2019, filed 14 Feb 2020.